UrsinaRTeitelbaumMD
Oncology • Philadelphia, PAAssociate Professor of Clinical Medicine, Perelman School of Medicine
Dr. Teitelbaum is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3400 convention Center Boulevard
South Tower 10
Philadelphia, PA 19104Phone+1 215-662-6319Fax+1 215-662-2432
Summary
- Dr. Ursina Teitelbaum is an oncologist in Philadelphia, PA and is affiliated with multiple hospitals in the area, including Hospital of the University of Pennsylvania, Penn Presbyterian Medical Center, and UPMC Presbyterian. She received her medical degree from University of Maryland School of Medicine and has been in practice 18 years. She also speaks multiple languages, including German and French. She is experienced in medical oncology, palliative medicine and geriatrics. Her subspecialty is gastrointestinal oncology.
Education & Training
University of ChicagoFellowship, Hematology and Medical Oncology, 2003 - 2005- University of ChicagoFellowship, Geriatric Medicine (Internal Medicine), 2002 - 2003
- University of ChicagoResidency, Internal Medicine, 1999 - 2002
University of Maryland School of MedicineClass of 1999
Certifications & Licensure
PA State Medical License 2006 - 2024
IL State Medical License 1999 - 2008
Awards, Honors, & Recognition
- Deenie Greitzer and Daniel G Haller Associate Professorship University of Pennsylvania, 2015-2016
- Academy of Master Clinicians University of Pennsylvania, 2014-2016
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer Start of enrollment: 2010 Sep 01
- Ph 3 ADI-PEG 20 Versus Placebo in Subjects With Advanced Hepatocellular Carcinoma Who Have Failed Prior Systemic Therapy Start of enrollment: 2011 Jul 01
Publications & Presentations
PubMed
- 2 citationsCirculating KRAS G12D but not G12V is associated with survival in metastatic pancreatic ductal adenocarcinoma.Jacob E Till, Lee McDaniel, Changgee Chang, Qi Long, Shannon M Pfeiffer
Nature Communications. 2024-07-09 - 1 citationsIntegrated Capecitabine-Temozolomide with Radioembolization for Liver-Dominant G2 NETs: Long-Term Outcomes of a Single-Institution Retrospective Study.Michael C Soulen, Ursina R Teitelbaum, Rosemarie Mick, Jennifer Eads, Jeffrey I Mondschein
Cardiovascular and Interventional Radiology. 2024-01-01 - 3 citationsThe Clinical Implications of Reversions in Patients with Advanced Pancreatic Cancer and Pathogenic Variants in BRCA1, BRCA2, or PALB2 after Progression on Rucaparib.Timothy J Brown, Arielle Yablonovitch, Jacob E Till, Jennifer Yen, Lesli A Kiedrowski
Clinical Cancer Research. 2023-12-15
Press Mentions
For Alex Trebek, the Toughest Question: Can He Face down Pancreatic Cancer?March 7th, 2019
Alex Trebek Has Stage 4 Pancreatic Cancer. Here's What That MeansMarch 7th, 2019
The Future of Pancreatic Cancer: A Conversation with Medical Oncologist Mark O'Hara, MDFebruary 11th, 2019- Join now to see all
Other Languages
- German, French
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
